Jpmorgan Chase & CO Larimar Therapeutics, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LRMR
# of Institutions
115Shares Held
67.7MCall Options Held
290KPut Options Held
38.9K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$158 Million3.23% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$45 Million0.66% of portfolio
-
Janus Henderson Group PLC London, X04.38MShares$32.6 Million0.02% of portfolio
-
Goldman Sachs Group Inc New York, NY4.33MShares$32.3 Million0.01% of portfolio
-
Blue Owl Capital Holdings LP New York, NY3.86MShares$28.8 Million11.62% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $322M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...